Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
Peer Reviewed Anatabine Study Published
Anatabine lowers Alzheimer's Aβ production in vitro and in vivo
Star Scientific Inc. (CIGX) Nasdaq
On Tuesday I was sent a scientific research abstract published in the European Journal of Pharmacology under the Molecular and Cellular Pharmacology heading, titled Anatabine lowers Alzheimer's Aβ production in vitro and in vivo.
This is the first of what I believe will be many peer review abstracts evaluated by leading scientific and medical journals, providing further credibility as to the beneficial effects of Anatabine / RCP-006 / Anatabloc™.*
The eight (8) page abstract validates the Roskamp Institute’s research and shows a statistically significant and dramatic inhibition of Aβ1–40 and Aβ1–42 production – that is, the substance which leads to amyloid formation and damage to brain tissue.
Riveting excerpts from the journal abstract:
· We observed that at a dose of 2 mg/kg, anatabine significantly lowers plasma CRP levels confirming that at this dosage anatabine displays an anti-inflammatory activity in vivo.
· We observed that anatabine dose dependently inhibited NFκB activation by TNFα in HEK293 NFκB luciferase reporter cells (Fig. 5) whereas nicotine was ineffective.
· A statistically significant reduction in plasma CRP levels was observed.
· We report for the first time that anatabine inhibits NFκB activation and may be a useful compound for regulating brain Aβ accumulation.
Link to the European Journal of Pharmacology abstract:
Michael Mullan, MD, Ph.D., Roskamp Institute co-director and one of the article's authors, commented, "This paper demonstrates anatabine's potential as an anti-inflammatory agent and shows it may have broad applications including for disorders like Alzheimer's Disease."
From what I understand there are numerous peer review studies underway and, as I have mentioned, these already submitted studies would not be published by Star, but by medical and scientific publications that have their own review process, timetable, and agenda. Exact timing is always an unknown. The submission history of the article excerpted above highlights that slog, as the piece was submitted for review before the Roskamp gathering that I attended on June 1, 2011.
At that meeting about 125 scientists, money managers, institutional investors, and assorted interested parties attended a tour and overview of important new discoveries being made at the distinguished Roskamp Institute. The conference lasted about four hours. In that time we were the recipients of a comprehensive recap and update of the science surrounding the "astonishing" anatabine compound RCP-006 (now Anatabloc™). The scientific part of the presentation included lead scientists and researchers from the Roskamp Institute and Johns Hopkins University School of Medicine. At the meeting Dr. Mullan reported that there are “no approved amyloid-reducing drugs,” and noted pointedly that the FDA would consider one the “Holy Grail” of treatment.
The plot-thickening narrative surrounding CIGX gets more compelling by the day. It has the feel of mythic consequence. This “first” peer review will now bring validity and credibility to the story that it still needed more of until this point. Human clinical trials at Roskamp are now underway and extensive pre-clinical research has been conducted. Obviously, the market for an effective drug for Alzheimer's would be met with resounding acceptance. The Alzheimer drug from Eli Lilly turned out to make Alzheimer’s worse, not better, and has been pulled off the market. A dozen other companies, including Pfizer and Johnson & Johnson, have been met with a string of study failures. There is no cure or even a treatment that has really shown to be successful in treating the affliction with its woefully grave prospects. According to a report from Alzheimer’s Disease International, around 35.6 million were afflicted with Alzheimer’s and other dementias in 2010, and cases are projected to rise to 115.4 million by 2050.
With statistics like that as a backdrop, I believe that it won't take long for the general public, especially early Alzheimer sufferers and their loved ones, to avail themselves of Star’s recently-released product Anatabloc™. Something momentous with the smell of a 60 Minutes spotlight or even a Nobel Prize could be underway here.
On Wednesday (8/30/2011) Star Scientific began selling Anatabloc™ online and by phone. See: http://anatabloc.com/
Peer review is a process of professional self-regulation, of research evaluation involving qualified individuals within a given field. Peer review methods are employed to maintain standards, improve performance, and ensure credibility.
For those who are not aware of the customary time period that peer review can take, the submission history from the article submitted to the European Journal of Pharmacology gives a useful example: Received 26 May 2011; Received in revised form 29 August 2011; Accepted 7 September 2011.
Today the study of inflammation, the cause of a multitude of pathologies, is preeminent in medical research and there are thousands of articles now referencing this “first” response of the immune system. To interrupt the negative cascade of the body’s response to this initial insult has become a central focus of medical research.
To view the Roskamp Institute ‘inflammaging research’ revealing how (RCP-006) Anatabloc™ is more than four (4) times more effective than either Celebrex or Voltarol and three (3) times more effective that Lipitor in reducing inflammation in whole human blood, see the links below:
* The commercial “launch” of Anatabloc™ is being orchestrated by marketing giant InVentiv Health (a Thomas H Lee Partners subsidiary), a leading marketing and distribution company with a client list that includes many of the largest, most successful pharmaceutical and biotech companies in the world, including Johnson & Johnson, Abbott Laboratories, Novartis, Merck, Pfizer, and Eli Lilly.
InVentiv, a $2 billion company, has marketing and sales capabilities in 40 countries around the globe. Thomas Lee Partners has invested approximately $22 billion of equity capital in more than 100 businesses with an aggregate purchase price of more than $150 billion.
Star has revealed that it is working with McColl Partners LLC “structuring a controlled auction for bidding by pharmaceutical companies for licensing and/or co-venturing relationships.”
I'm an investor in Star Scientific shares and have bought shares the open market and have no other affiliation with the company other than as a shareholder.